Travere Therapeutics' Gains from Investment Securities rose 146.04% to $807,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.4 million, marking a year-over-year increase of 80.28%. This contributed to the annual value of -$7.9 million for FY2024, which is 319.08% down from last year.
Latest data reveals that Travere Therapeutics reported Gains from Investment Securities of -$7.9 million as of FY2024, which was down 319.08% from $3.6 million recorded in FY2023.
Travere Therapeutics' Gains from Investment Securities' 5-year high stood at $3.6 million during FY2023, with a 5-year trough of -$16.4 million in FY2021.
Moreover, its 3-year median value for Gains from Investment Securities was -$1.3 million (2022), whereas its average is -$1.9 million.
As far as peak fluctuations go, Travere Therapeutics' Gains from Investment Securities soared by 369.39% in 2023, and later slumped by 319.08% in 2024.
Yearly analysis of 5 years shows Travere Therapeutics' Gains from Investment Securities stood at -$12.4 million in 2020, then plummeted by 32.34% to -$16.4 million in 2021, then spiked by 91.80% to -$1.3 million in 2022, then soared by 369.39% to $3.6 million in 2023, then crashed by 319.08% to -$7.9 million in 2024.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value